GREENSBORO, N.C., April 14, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, maker of XEOMIN® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign. With the help of patient advocates, "Make Your Mark" celebrates the inspirational stories of people living with blepharospasm or cervical dystonia (CD), also known as spasmodic torticollis, and aims to raise awareness of these often debilitating conditions.
XEOMIN is approved in the U.S. to treat the abnormal head position and neck pain that happens in adults with cervical dystonia, as well as the abnormal spasms of the eyelids (blepharospasm) in adults who have had prior treatment with onabotulinumtoxinA (Botox®).
Photos/Multimedia Gallery Available: http://www.news2know.net/mnr/merz/make-your-mark.php 
"For those who suffer with chronic conditions like cervical dystonia or blepharospasm, self-expression and creativity play a part in how we feel," said Hallie Neill, an accomplished opera singer, actress and writer who was diagnosed with cervical dystonia in 2007. "When we express ourselves creatively through writing stories, making music, painting, cooking and dancing, we inspire ourselves and others, and make a positive mark on the world around us."
Cervical dystonia and blepharospasm are thought to be rare conditions but are possibly undiagnosed or misdiagnosed due to the lack of specific clinical criteria. According to a recent online survey conducted by Harris Interactive on behalf of Merz Pharmaceuticals, LLC, an average of 55 percent of cervical dystonia and blepharospasm patients surveyed reported that they experienced symptoms for one year or more before their conditions were diagnosed. In fact, 66 percent of surveyed patients on average say they were not diagnosed sooner because there is a lack of knowledge about thes